Shanghai Pharmaceuticals Holding and Yunnan Baiyao Renew Sales Agreement for 2025

MT Newswires Live01-02

Shanghai Pharmaceuticals Holding (HKG:2607) said its sales and procurement framework agreement between Shanghai Pharmaceuticals Holdings and Yunnan Baiyao expired on Dec. 31, but both companies are committed to continuing their transactions.

On the same day, the board approved and executed the agreement, effective from Jan. 1, 2025, to Dec. 31, 2025, for mutual sales and procurement of various medical and health products, according to its filing on Wednesday.

Yunnan Baiyao, holding a 17.95% stake in the company, is a substantial shareholder and thus a connected person as per the Listing Rules.

Consequently, the transactions under this new agreement are classified as continuing connected transactions, requiring reporting and annual review but exempt from circular and independent shareholders' approval due to the applicable percentage ratios.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500458659?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-02 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500458659","market":"sh","top_or_hot":-1,"title":"Shanghai Pharmaceuticals Holding and Yunnan Baiyao Renew Sales Agreement for 2025","media":"MT Newswires Live","content":"<html><body><p> Shanghai Pharmaceuticals Holding (HKG:2607) said its sales and procurement framework agreement between Shanghai Pharmaceuticals Holdings and Yunnan Baiyao expired on Dec. 31, but both companies are committed to continuing their transactions.</p><p>On the same day, the board approved and executed the agreement, effective from Jan. 1, 2025, to Dec. 31, 2025, for mutual sales and procurement of various medical and health products, according to its filing on Wednesday.</p><p>Yunnan Baiyao, holding a 17.95% stake in the company, is a substantial shareholder and thus a connected person as per the Listing Rules.</p><p>Consequently, the transactions under this new agreement are classified as continuing connected transactions, requiring reporting and annual review but exempt from circular and independent shareholders' approval due to the applicable percentage ratios.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals Holding and Yunnan Baiyao Renew Sales Agreement for 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals Holding and Yunnan Baiyao Renew Sales Agreement for 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-02 18:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shanghai Pharmaceuticals Holding (HKG:2607) said its sales and procurement framework agreement between Shanghai Pharmaceuticals Holdings and Yunnan Baiyao expired on Dec. 31, but both companies are committed to continuing their transactions.</p><p>On the same day, the board approved and executed the agreement, effective from Jan. 1, 2025, to Dec. 31, 2025, for mutual sales and procurement of various medical and health products, according to its filing on Wednesday.</p><p>Yunnan Baiyao, holding a 17.95% stake in the company, is a substantial shareholder and thus a connected person as per the Listing Rules.</p><p>Consequently, the transactions under this new agreement are classified as continuing connected transactions, requiring reporting and annual review but exempt from circular and independent shareholders' approval due to the applicable percentage ratios.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02607","symbol_name":"上海医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2500458659","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500458659","pubTimestamp":1735812155,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Pharmaceuticals Holding  said its sales and procurement framework agreement between Shanghai Pharmaceuticals Holdings and Yunnan Baiyao expired on Dec. 31, but both companies are committed to continuing their transactions.On the same day, the board approved and executed the agreement, effective from Jan. 1, 2025, to Dec. 31, 2025, for mutual sales and procurement of various medical and health products, according to its filing on Wednesday.Yunnan Baiyao, holding a 17.95% stake in the company, is a substantial shareholder and thus a connected person as per the Listing Rules.Consequently, the transactions under this new agreement are classified as continuing connected transactions, requiring reporting and annual review but exempt from circular and independent shareholders' approval due to the applicable percentage ratios.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"02607":"上海医药"},"translate_title":"上药控股与云南白药续签2025年销售协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02607":0.9},"content_text":"Shanghai Pharmaceuticals Holding (HKG:2607) said its sales and procurement framework agreement between Shanghai Pharmaceuticals Holdings and Yunnan Baiyao expired on Dec. 31, but both companies are committed to continuing their transactions.On the same day, the board approved and executed the agreement, effective from Jan. 1, 2025, to Dec. 31, 2025, for mutual sales and procurement of various medical and health products, according to its filing on Wednesday.Yunnan Baiyao, holding a 17.95% stake in the company, is a substantial shareholder and thus a connected person as per the Listing Rules.Consequently, the transactions under this new agreement are classified as continuing connected transactions, requiring reporting and annual review but exempt from circular and independent shareholders' approval due to the applicable percentage ratios.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500458659"}